FDA updates ibuprofen compounding guidance
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products to help hospitals and health systems meet demand for fever-reducing products to treat pediatric patients and adults unable to swallow solid oral dosage forms. The revision addresses outsourcing facilities providing certain ibuprofen oral suspension products to dispense to patients for home use after receiving a patient-specific prescription from a health care provider.
Related News Articles
Headline
The Administration for Strategic Preparedness and Response announced Nov. 3 that it will partner with the Bureau of Industry and Security and the Assistant…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The median annual net launch price for new prescription drugs increased 35% from 2022 to 2025, to $257,000, according to a report released by the Institute for…
Headline
A survey released Sept. 10 by the National Comprehensive Cancer Network highlights ongoing shortages of cancer medications. All responding cancer centers…
Headline
The Food and Drug Administration July 10 released a proposed rule that would modernize drug establishment registration requirements, with implications for…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…